Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Gross Profit (2022 - 2025)

Historic Gross Profit for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $230.0 million.

  • Indivior Pharmaceuticals' Gross Profit fell 456.43% to $230.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $949.0 million, marking a year-over-year increase of 10.55%. This contributed to the annual value of $957.0 million for FY2024, which is 413.49% up from last year.
  • As of Q3 2025, Indivior Pharmaceuticals' Gross Profit stood at $230.0 million, which was down 456.43% from $250.0 million recorded in Q2 2025.
  • Indivior Pharmaceuticals' 5-year Gross Profit high stood at $250.0 million for Q2 2025, and its period low was $183.0 million during Q2 2022.
  • Over the past 4 years, Indivior Pharmaceuticals' median Gross Profit value was $225.5 million (recorded in 2023), while the average stood at $223.9 million.
  • Its Gross Profit has fluctuated over the past 5 years, first surged by 2349.73% in 2023, then plummeted by 1016.26% in 2025.
  • Quarter analysis of 4 years shows Indivior Pharmaceuticals' Gross Profit stood at $198.0 million in 2022, then grew by 21.72% to $241.0 million in 2023, then grew by 2.9% to $248.0 million in 2024, then decreased by 7.26% to $230.0 million in 2025.
  • Its Gross Profit stands at $230.0 million for Q3 2025, versus $250.0 million for Q2 2025 and $221.0 million for Q1 2025.